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Abstract
Heterozygous mutations in NADP-dependent isocitrate dehydro-
genases (IDH) define the large majority of diffuse gliomas and
are associated with hypermethylation of DNA and chromatin.
The metabolic dysregulations imposed by these mutations,
whether dependent or not on the oncometabolite D-2-hydroxy-
glutarate (D2HG), are less well understood. Here, we applied
mass spectrometry imaging on intracranial patient-derived xeno-
grafts of IDH-mutant versus IDH wild-type glioma to profile the
distribution of metabolites at high anatomical resolution in situ.
This approach was complemented by in vivo tracing of labeled
nutrients followed by liquid chromatography–mass spectrometry
(LC-MS) analysis. Selected metabolites were verified on clinical
specimen. Our data identify remarkable differences in the phos-
pholipid composition of gliomas harboring the IDH1 mutation.
Moreover, we show that these tumors are characterized by
reduced glucose turnover and a lower energy potential, correlat-
ing with their reduced aggressivity. Despite these differences,
our data also show that D2HG overproduction does not result in
a global aberration of the central carbon metabolism, indicating
strong adaptive mechanisms at hand. Intriguingly, D2HG shows
no quantitatively important glucose-derived label in IDH-mutant
tumors, which suggests that the synthesis of this oncometabo-
lite may rely on alternative carbon sources. Despite a reduction
in NADPH, glutathione levels are maintained. We found that
genes coding for key enzymes in de novo glutathione synthesis
are highly expressed in IDH-mutant gliomas and the expression
of cystathionine-b-synthase (CBS) correlates with patient survival
in the oligodendroglial subtype. This study provides a detailed
and clinically relevant insight into the in vivo metabolism of
IDH1-mutant gliomas and points to novel metabolic vulnerabili-
ties in these tumors.
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Introduction
Gliomas are a heterogeneous group of glial-derived brain tumors, the
majority of which have a poor prognosis. The identification of
heterozygous point mutations in the genes encoding for isocitrate
dehydrogenase (IDH) 1 and 2 has been a breakthrough in the under-
standing of possible causes of glioma genesis (Parsons et al, 2008).
IDHmutations are present in the vast majority of lower grade gliomas
and define a subtype with a favorable prognosis (Hartmann et al,
2009; Yan et al, 2009). They have recently been recognized as the
major determinant in the molecular classification of diffuse gliomas
(Cancer Genome Atlas Research et al, 2015; Ceccarelli et al, 2016).
Of the two isoforms associated with tumorigenesis, cytosolic IDH1 is
the most commonly mutated, while the mitochondrial IDH2 isoform
represents < 5% of mutant cases (Hartmann et al, 2009). Interestingly
while IDH1 and IDH2 are NADP+-dependent enzymes, themitochondrial
NAD-dependent IDH3 isoform has not been associated with mutations.
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IDH enzymes are b-decarboxylating dehydrogenases that cata-
lyze the reversible reaction of isocitrate to a-ketoglutarate (aKG,
also known as 2-oxoglutarate), while generating NADPH and CO2.
The cancer-associated mutation of IDH (IDHm) has gained a
neomorphic activity whereby aKG is converted to D-2-hydroxygluta-
rate (D2HG) while oxidizing NADPH. This reaction produces a 50-
to 100-fold increase in D2HG levels in cells carrying the mutation
(Dang et al, 2009). Established as an oncometabolite, D2HG has
been shown to competitively inhibit TET methylcytosine dioxyge-
nases, as well as JmjC domain-containing histone demethylases,
thus resulting in global hypermethylation of DNA and chromatin
(Xu et al, 2011). Recent data confirmed that IDHm is at the origin of
epigenetic instability in glioma cells, leading to hypermethylation of
CpG islands (G-CIMP phenotype) and histones H3 and H4 (Duncan
et al, 2012; Turcan et al, 2012).
Next to these epigenetic alterations, these tumors are likely to
harbor D2HG-independent metabolic abnormalities linked to the loss
of the normal function of IDH, which plays a major role in, for exam-
ple, the control of mitochondrial redox balance and cellular defense
against oxidative damage (Jo et al, 2001; Lee et al, 2002). The onco-
genic adaptations at the metabolic level are, however, incompletely
understood because of a lack of appropriate cell culture and animal
models. Glioma cells carrying an endogenous IDH mutation are
notoriously difficult to grow in culture or to expand in vivo in rodent
models, and if so, they grow very slowly. Only a handful of patient-
derived xenografts (PDX), including ours, have been described in
the literature (Luchman et al, 2012; Klink et al, 2013; Navis et al,
2013). While glioblastoma (GBM) cell lines engineered to overex-
press the mutant enzyme have served as useful models for metabolic
profiling (Reitman et al, 2011; Mohrenz et al, 2013; Ohka et al,
2014; Shi et al, 2014), this set up harbors some limitations: The
mutation is introduced out of the appropriate genetic background,
the stoichiometric balance of the mutant versus wild-type form
(IDHwt) is disrupted, and the specificities of the brain microenviron-
ment, likely to impact cellular metabolism, are not maintained.
Metabolite profiling is further hampered by intrinsic limitations of
available analytical technologies in as such that no single methodol-
ogy can provide a comprehensive metabolic landscape.
In an attempt to shed light on the mechanistic link between IDH
mutations and oncometabolic adaptations, we profiled the in vivo
metabolic content of patient-derived glioma xenografts and clinical
glioma samples with or without the IDH mutation. Using mass spec-
trometry-based imaging (MSI) on brain sections, we provide an
anatomical distribution of metabolites, complemented by liquid
chromatography–mass spectrometric (LC-MS) analyses and in vivo
metabolic tracer studies. Our data show major alterations in lipid
metabolism, significant adaptations in the central energy metabo-
lism, and oxidative stress pathways in IDHm gliomas, pointing
to novel metabolic vulnerabilities that may be therapeutically
exploitable.
Results
Altered lipid metabolism in IDH1-mutant glioma xenografts
We have previously generated intracranial patient-derived xeno-
grafts (PDXs) of glioblastoma (GBM) and have shown that such
tumors recapitulate human GBM growth patterns, retaining pheno-
typic and genetic aberrations of the parental tumors (Fack et al,
2015; Bougnaud et al, 2016). In comparison, PDXs of lower grade
diffuse gliomas carrying the IDH mutation have long been difficult
to establish, and no cell culture models of these glioma subtypes
exist. Recently, we and others have been able to implant such PDX
and maintain them by serial transplantation in the brain of immun-
odeficient mice (Luchman et al, 2012; Klink et al, 2013; Navis et al,
2013). IDHm glioma PDXs display IDH1m immunoreactivity and a
more than 50-fold increase in D2HG levels in the tumor area
compared to IDHwt PDXs (Navis et al, 2013) and in line with their
clinical behavior develop very slowly in the mouse brain (between
2–10 months). Nevertheless, such experimental models allow for
the first time a comparative metabolomic analysis of different
glioma subtypes in the brain microenvironment. To this aim, we
profiled brain sections of three IDHm and three IDHwt glioma xeno-
grafts by MSI to generate in situ distribution maps of tumor metabo-
lites (Fig 1A). This strategy comprised a large-scale untargeted
analysis performed on small regions of interest (ROI) and a targeted
approach to quantify the distribution of selected metabolites in a
large ROI (Fig 1A). Comparison to control mouse brain tissue (CB)
served to calibrate the data for reliable comparison between tumors.
IDHwt PDXs (P3, T434, P8) were GBM-derived, while IDHm PDXs
contained two lower grade gliomas (LGG: E478, T186) and one
glioblastoma (T394) (see diagnostic details in Table 1). It should be
noted that the new WHO classification for brain tumors (Louis et al,
2016) has introduced the IDH status as a defining feature of glioma
subtype and largely separates lower grade diffuse gliomas (IDHm)
from grade IV glioblastoma (IDHwt). The inclusion of a relatively
rare IDHm GBM should allow to distinguish metabolic effects inher-
ent to IDH status or linked to tumor grade.
To get an unbiased overview of major differences, we first
performed untargeted profiling on three samples (IDHm and IDHwt
PDX and normal control brain (CB)) revealing more than 100
metabolites unevenly distributed between IDHm versus IDHwt
gliomas (Tables EV1–EV3). Interestingly, many of the top metabo-
lites had a relatively high mass range (as indicated by their mass-
to-charge ratio (m/z) > 600), often representing metabolites of
unknown identity. Although not all mass ratios could be attributed
to a specific metabolite, the majority was tentatively assigned
using Metlin, HMBD or an internal metabolite database. To those
entities matching multiple isobaric compounds, several metabolite
identities were assigned (Tables EV2 and EV3). Striking differences
associated with IDH status were found in phospholipid
compounds, including phosphatidylethanolamine (PE), phos-
phatidylinositol (PI), phosphatidylserine (PS), phosphatidylcholine
(PC), and phosphoglycerol (PG), indicating major aberrations in
lipid composition of IDHm tumors. Using the targeted MSI
approach, we verified the detection of selected metabolites in all
six PDX samples. Figure 1B depicts the distribution of D2HG in
IDHm PDX allowing to clearly identify the tumor region on brain
sections. D2HG levels were very high in all IDHm PDXs (at least
50-fold), as confirmed by LC-MS (Fig EV1A). Several higher mass
metabolites (e.g., m/z 778.47; m/z 807.53) were accumulated in
IDHm gliomas, with much lower detection in IDHwt tumors
(Fig 1B and C; MSI images in Fig EV1B). Some of them were also
present in fiber tracts of normal brain areas (see, e.g., m/z 778.47
in Fig EV1B). Interestingly, two putative phospholipids (m/z ratio
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Figure 1. MALDI imaging for in situ metabolic profiling of gliomas reveals aberrant phospholipid metabolism in IDH-mutant glioma.
A MALDI imaging was performed on tumor-containing brain sections at a lateral resolution of 100 lm, and (M-H) ions were analyzed in negative mode with a FTICR
mass spectrometer (analytical range 100–1,000 Da). Hematoxylin–eosin (HE) staining of the same sections was performed after MALDI analysis. Patient-derived
glioma xenografts (PDXs) with IDH1 wild type (IDH1wt), IDH1 mutant (IDH1m), and control brain tissue (CB) were analyzed in a non-targeted and targeted approach
using regions of interest (ROI) of different sizes to compare tumor (T, yellow line) and contralateral control brain (CB, blue line). The non-targeted approach was used
for statistical pair-wise comparisons between samples, while the targeted approach on a selected set of metabolites allowed distribution and quantification analyses.
B Histological sections of three IDH1wt PDXs (P3, T434, and P8) and three IDH1m PDXs (T394, E478, and T186) showing a large ROI (boxed rectangle, > 500 pixels)
within the tumor area applied for targeted quantification of selected metabolites. Left rectangle in P3 PDX was used as control contralateral brain (CB) for
quantifications. Middle panel shows tissue distribution of D-2-hydroxyglutarate (D2HG) by MSI, which is exclusively detected in IDH1m PDXs (D2HG in IDH1wt
tumors is below detection limit). Right panel shows tissue distribution of a key metabolite (m/z 778.51) presenting strong accumulation in IDH1m lower grade
gliomas (LGG) versus glioblastomas (GBM) independent of IDH status. An intensity-dependent color code indicates the relative amount of a specific compound
(defined by m/z value) throughout the tissue section.
C Quantification of several high mass metabolites differentially present in IDH1m PDXs (IDH1wt glioblastomas (GBM) in blue, IDH1m GBM in orange, IDH1m lower grade
gliomas (LGG) in red, and contralateral control brain (CB) in gray). Box plots represent log values of metabolite intensities measured within a large ROI (> 500 pixels). Box
limits indicate the 25th and 75th percentiles and center lines show the medians as determined by R software; whiskers represent the extreme low and high observed
values, unless those are above 1.5 times interquartile range (IQR) – thereby whiskers are limited to 1.5 IQR. All outlying data points are represented by dots. Many
metabolites in this mass range (m/z 700–900) have been putatively assigned to phospholipids (Tables EV2 and EV3).m/z represents the mass over charge ratio of ionized
metabolites, as measured by the mass spectrometer. The statistical significance was calculated for IDH1m (n = 3) versus IDH1wt (n = 3) PDXs using t-test. Pv: P-values.
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of 778.51 and m/z 821.53) appeared specifically enriched in lower
grade IDHm PDX compared to GBMs (Fig 1C; m/z 778.51 more
than 1,000-fold increase, Table EV2), thus correlating with grade
rather than IDH status. Similar to D2HG, IDHm-specific metabo-
lites were restricted to the tumor area, with limited diffusion/
extension toward adjacent brain areas, yet MSI allowed to detect
intra-tumoral metabolic heterogeneity (Fig 1B). In summary, these
data reveal drastic alterations in the composition of phospholipid
and other high mass metabolites, some of them being related to
tumor grade. Although the unequivocal identification of these
metabolite species remains to be determined, they may represent
putative novel biomarkers for IDH-mutant gliomas.
IDH-mutant glioma display reduced energy potential
Targeted MSI was further focused on phospho-metabolites related to
cellular energy pathways. Hexose phosphates (Hex-P) showed
increased levels in all tumors compared to normal brain, indicative
of enhanced glucose uptake (Fig 2A, quantification in Fig EV1B).
Similarly, adenosine diphosphate (ADP) and adenosine triphosphate
(ATP) nucleotides were increased in tumors compared to the brain
(Fig 2A, quantification Fig EV1B). However, while adenosine
monophosphate (AMP) and ADP levels were similar in all tumors,
ATP levels were lower in IDHm compared to IDHwt PDX, as quanti-
fied by LC-MS (Fig 2B). As a result, the overall energetic charge
index (defined as ATP+0.5ADP/(ATP+ADP+AMP)) was significantly
lower in IDHm gliomas (Fig 2C and D). This correlated with the
generally lower proliferation index of IDHm xenografts (e.g., MIB
index based on Ki67 staining was 21.8  3% for E478 and
54.7  2% for P3 PDX) and the slower tumor development in mice
(Table 1), which is also in agreement with the better prognosis of
IDHm glioma patients observed in the clinic. Similar to D2HG, the
energy charge distribution displayed a gradient from the tumor core
to the periphery (Fig 2C), which may reflect a reduced ratio of
cancer versus non-neoplastic cells. Sedoheptulose-7-P (Sdh7-P), an
intermediate of the pentose phosphate pathway and a precursor of
ribose phosphate, was also lower versus high grade gliomas
(Fig 2B), in line with a reduced de novo biosynthesis of nucleotides.
In summary, these data indicate a reduced energy potential in IDHm
gliomas that may explain the relatively low proliferation rate of this
subtype of brain tumors.
Metabolic flux toward aKG and D2HG is unresolved in
IDHm gliomas
In order to understand the origin of reduced energy potential in
IDHm gliomas, we applied LC-MS to quantify steady-state level of
glucose-derived metabolites in the six PDXs and performed in vivo
tracing of isotope-labeled metabolites after injection of 13C6-glucose
in two PDXs. There was a tendency toward reduced levels of
glucose-derived metabolites (e.g., pyruvate, lactate, citrate) in IDHm
tumors, which reached significance for the tricarboxylic acid (TCA)
cycle intermediates aKG and malate (Fig 3A). A similar tendency
was also observed in a set of clinical glioma samples analyzed by
LC-MS (7 IDHwt versus 6 IDHm), where a significant drop in pyru-
vate was noted (Fig EV4). Of note, the metabolite levels of the
Table 1. Neuropathological diagnostics and genetic characterization of samples used for patient-derived xenografts.
Xenografts
Histopathological
diagnosis
Molecular
pathology
(methylation
score)
Survival
(days)
IDH
status
1p/19q
Codel
ATRX
mutation
CDKN2A/B
deletion
RTK
amplified
Gain of
Chr7
Loss of
Chr10
E478 Oligodendroglioma
grade III
NA 73 days IDH1-
R132Hb
Yesa NA Noa Noa Yesa Yesa
T186 Anaplastic
oligodendroglioma
grade III
NA 107 days IDH1-
R132Hb
Noa Yesb (E1473) Noa Noa Noa Partiala
T394 Glioblastoma
grade IV
Glioma, IDH
mutant,
subclass
high-grade
astrocytoma
(0.99)
77 days IDH1-
R132Hb
Partiala Unclear
significanceb, c
Yesa PDGFRAa Noa Partiala
P3 Glioblastoma
grade IV
NA 40 days Nob Noa Nob Yesa Noa Yesa Partiala
P8 Glioblastoma
grade IV
NA 58 days Nob
(V178I)
Noa Unclear
significanceb, d
Yesa EGFRa Yesa Yesa
T434 Glioblastoma
grade IV
Glioblastoma,
IDH wild-type
(0.99)
42 days Nob Noa Nob Noa EGFRa Partiala Yesa
NA: not assessed; ATRX E1473: Nonsense mutation, SIFT & Polyphen-2 score deleterious.
IDH1 V178I – no functional domain affected, 2-HG unaffected.
aArray comparative genomic hybridization.
bTargeted next generation sequencing.
cATRX Q891E – hypomorphic mutation, protein features might be affected; additional 15 missense mutations with unclear significance.
dATRX Q891E – hypomorphic mutation, protein features might be affected; additional S502C missense mutation with unclear significance.
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Figure 2. IDH-mutant gliomas display a low energy potential.
A MALDI imaging of indicated metabolites in IDHwt PDX (P3), IDHm PDX (E478), and control brain (CB). Hex-P: hexose phosphate; AMP, ADP, ATP: adenosine mono-, di-,
and triphosphate, respectively.
B LC-MS quantification of indicated metabolites in six PDXs. Relative quantities of metabolites are expressed in log scale and normalized to tissue quantity used for
extract preparation. IDHwt glioblastomas (GBM) in blue, IDHm GBM in orange, IDHm lower grade gliomas (LGG) in red, contralateral control brain (CB) in gray.
Sdh7-P: sedoheptulose-7-phosphate (n = 3/sample/group).
C Energetic charge defined as the ratio of (ATP+1/2ADP)/(ATP+ADP+AMP) was calculated at each pixel to present its distribution throughout the tumor. Scale bar: 8.2 mm.
D The energetic charge ratio was confirmed by the LC-MS data performed on separate tumor extracts (n = 3/sample/group).
Data information: The indicated statistically significant group differences are based on t-test, Pv: P-values. Error bars in (B and D) represent standard error of the mean.
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IDHm GBM (in orange) appeared occasionally closer to the GBM
group than to the IDHm lower grade tumors.
To gain a better understanding of the flux of glucose carbons
in IDHm gliomas, 13C6-glucose was injected in two PDXs (E478
and P3) 20 min before sacrifice (Fig 3B–D). We observed a reduc-
tion in 13C-labeled lactate, pyruvate and malate in IDHm tumors
compared to IDHwt, suggesting a reduced turnover of glucose
metabolism (Fig 3D). Surprisingly, we did not detect heavy
isotopologues of aKG and D2HG in IDHm gliomas (Fig 3C). This
was in sharp contrast to IDHwt tumors and contralateral brain
regions, where a significant fraction of 13C2 isotopologues were
present in both aKG and D2HG (Fig 3C and D). Although a small
A
B C
D
Figure 3. In vivo metabolic flux analysis indicates a reduced glucose turnover in IDH-mutant glioma.
A LC-MS quantification of steady-state level of glycolysis and TCA cycle metabolites in three IDH1wt and three IDH1m PDXs and contralateral control brain (CB)
(n = 3/sample/group). Error bars represent standard error of the mean. Metabolites showing statistically significant group differences between IDH1wt and IDH1m
are indicated (P-value < 0.05). Color code as in Figs 1 and 2. Indicated statistical significant group differences are based on t-test, Pv: P-values.
B Schematic of 13C6 glucose-derived carbon flux to pyruvate and TCA metabolites, highlighting expected
13C2 and
13C3 labels (in red) in intermediate metabolites.
C In vivo flux analysis of 13C-labeled glucose injected 20 min prior to sacrifice in one IDH1wt PDX (P3) and one IDH1m PDX (E478) (n = 3/sample). The percentage of glucose-
derived 13C label is shown in selected metabolites containing 0 to 6 13C atoms (13C0-
13C6 as indicated by color code). Note the absence of
13C2 label of aKG and D2HG in
IDHm tumors, while the label was detectable in IDHwt PDX and in contralateral brain of both tumors (lower panel). Error bars represent standard error of the mean.
D Quantities of 13C3- and
13C2-labeled metabolites from glucose tracer experiment in (C). D2HG in IDH1m PDX shows a detectable
13C2 signature here, but represents a
minor fraction of the total cellular D2HG pool in this tumor. Hex-P: hexose phosphate, PEP: phosphoenolpyruvate, Pyr: pyruvate, Cit: citrate, Mal: malate, Asp:
aspartate, Glu: glutamate, Gln: glutamine, a-KG: a-ketoglutarate, D2HG: D2-hydroxyglutarate. Error bars represent standard error of the mean.
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amount of 13C2-labeled D2HG was seen in the IDHm tumor
(Fig 3D), this fraction is negligible compared to total D2HG levels
in this tumor. As the overall amount of aKG was comparably low
in contralateral brain and IDHm tumor tissues (Fig 3A), the
absence of labeling in the latter cannot simply be explained by
falling below the detection limit. This suggested that mitochon-
drial IDH2 does not efficiently compensate glucose-derived aKG
production in this setting and raised the question of the carbon
source for aKG and D2HG in IDHm tumors. In an attempt to
address this, we traced 13C5-glutamine in IDHm and IDHwt PDXs.
Reliance on glutamine for anaplerosis implies the deamination of
glutamine to glutamate by glutaminase in the mitochondrion,
where glutamate can be further deaminated to aKG to replenish
the TCA cycle. However, only a very small amount of 13C5-gluta-
mine was found in the tumors irrespective of their IDH status,
and the heavy isotopologues of glutamine derivatives were not
detectable, neither in control brain nor in tumors (Fig EV2). This
is in agreement with our previous observation in GBM xenografts,
confirming that in the mouse brain, glutamine is hardly taken up
from the circulation (Tardito et al, 2015). It remains to be seen to
what extent brain-derived glutamine or glutamate plays a role as
bioenergetic substrates in IDHm gliomas. It should be noted,
however, that based on the high level of glucose-derived gluta-
mine and glutamate isotopologues detected in control brain
(Fig 3C lower panel), it is surprising to see that this was not
translated in 13C2-labeling of aKG and D2HG in the tumor.
Alterations in amino acids and neurotransmitters in
IDH-mutant glioma
Glutamine is thought to be an important nutrient in cancer (DeBer-
ardinis & Cheng, 2010), and IDHm tumors have been proposed to
be particularly dependent on glutamine (Seltzer et al, 2010; Emadi
et al, 2014), however, whether this holds true in the brain milieu
with its distinct metabolite composition remains to be determined.
In glioma PDXs, we found no relevant difference in glutamine and
glutamate levels between IDHwt and IDHm tumors by MSI,
although glutamate was reduced compared to control brain (Fig 4A
and B), which was validated by LC-MS analysis (Fig EV3). LC-MS
on clinical glioma samples confirmed similar glutamine levels in all
gliomas, while a reduction in glutamate was detected in IDHm
glioma patients (Fig EV4). Although this may suggest an increased
reliance on glutamate rather than glutamine in these tumors, it is
currently not clear why this observation was not reproduced in the
PDX models.
Similar to glutamate, MSI showed a strong reduction in the exci-
tatory amino acid neurotransmitter aspartate and its derivative
N-acetyl-aspartate (NAA) in tumors compared to control brain, inde-
pendent of IDH status (Fig 4A and B). NAA can be hydrolyzed by
aspartoacylase (ASPA) to produce aspartate and acetate (Tsen et al,
2014) which was recently identified as a major bioenergetic
substrate in brain tumors (Mashimo et al, 2014). NAA is also a
substrate for the synthesis of N-acetylaspartylglutamate (NAAG), a
A
B
Figure 4. Distribution of selected amino acids in gliomas.
A MALDI imaging of key metabolites in IDH1wt (P3) and IDH1m (E478) glioma
PDX, compared to control brain (CB) sections. Scale bar: 8.2 mm. Red arrow
indicates brain region with high NAAG content.
B Quantification of metabolite distribution by MSI in six PDX with IDH1wt
and IDH1m status (n = 3/group) and in contralateral control brain (CB). Box
limits indicate the 25th and 75th percentiles and center lines show the
medians as determined by R software; whiskers represent the extreme low
and high observed values, unless those are above 1.5 times interquartile
range (IQR) – thereby whiskers are limited to 1.5 IQR. All outlying data
points are represented by dots. No significant differences between IDH
groups were detected by t-test on the means, although significant
differences are found between tumors and control brain (glutamate,
aspartate). Color code as in Fig 1. NAA: N-acetylaspartic acid; NAAG:
N-acetylaspartylglutamic acid.
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Figure 5. Oxidative stress response in IDH wild-type and IDH-mutant glioma.
A NADPH levels are reduced in IDHm compared to wild-type tumors, resulting in a reduced NADPH/NAD+ ratio (n = 3/sample). Error bars represent standard deviation.
P-value from t-test: < 0.05. NADPH, NADP: reduced, oxidized nicotinamide adenine dinucleotide phosphate, NADH, NAD: reduced, oxidized nicotinamide adenine dinucleotide.
B MALDI images for glutathione (GSH) and cystathionine on IDH1wt (P3) and IDH1m (E478) PDXs. Quantification of MSI signals for GSH and cystathionine from 6 PDXs
(n = 3/group). Box limits indicate the 25th and 75th percentiles and center lines show the medians as determined by R software; whiskers represent the extreme low
and high observed values, unless those are above 1.5 times interquartile range (IQR) – thereby whiskers are limited to 1.5 IQR. All outlying data points are represented by dots.
C LC-MS quantification of independent samples for GSH, GSSG (oxidized GSH), GSSG/GSH ratio and cystathionine from 6 PDXs (n = 3/sample/group). Statistical
significance between IDH groups calculated by t-test, Pv: P-value. Error bars represent standard error of the mean.
D Schematic of GSH synthesis, cysteine supply, and its degradation pathways. GSH: reduced glutathione; GSSG: oxidized glutathione; SAM: S-adenosylmethionine, SAH:
S-adenosylhomocysteine, CSA: cysteine sulfinic acid. Key enzymes in red: CBS: cystathionine-beta-synthase, GCL: glutamate-cystine ligase, xCT: cysteine-glutamate antiporter.
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Figure 6. CBS is a prognostic biomarker for patients with IDH-mutant 1p/19q co-deleted gliomas.
A Comparative gene expression analysis of key enzymes involved in GSH and cysteine synthesis and supply in IDHwt (n = 220), IDHm with 1p/19q co-deletion
(n = 151), or IDHm without 1p/19q co-deletion (n = 226) patients based on TCGA RNA-seq data from a cohort of 597 patients. CBS: Cystathionine-beta-synthase,
key enzyme of the transsulfuration pathway. GCLC: catalytic subunit of glutamate-cysteine ligase. SLC7A11: gene encoding xCT, the cystine-glutamate antiporter.
Center lines of the box plots show the medians; box limits indicate the 25th and 75th percentiles, outliers are represented by dots. Notches indicate 1.58 × IQR/sqrt(n)
and gives 95% confidence that two medians differ. Whiskers extend 1.5 times the interquartile range from the 25th and 75th percentile. Statistical test: Wilcoxon rank
sum test with continuity correction. Pv: P-value, ns: non-significant.
B Kaplan–Meier curves of CBS gene expression versus overall survival in patients with IDHwt, IDHm with or without 1p/19q co-deletion. Comparison of survival curves
was done using Log-rank (Mantel-Cox) test.
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neuropeptide abundant in specific brain areas, as seen by MSI of
normal mouse brain (arrow in Fig 4A). While NAAG was not detect-
able in IDHwt PDXs, it showed high variability in IDHm tumors
(Fig 4A). Identification of NAA and NAAG was validated by MALDI
using isotopically labeled reference compounds (not shown), and
quantification was confirmed by LC-MS (Fig EV3). Similar data
were also found in clinical IDHm samples analyzed by LC-MS
(Fig EV4), where two NAAG subpopulations were observed: Three
of six displayed high levels of NAAG while the remaining three
displayed levels similar to IDHwt samples, suggesting activation of
different metabolic pathways independent of available biomarker
status (IDH, 1p/19q, or methylation status; Table EV6).
The antioxidant response in IDH-mutant gliomas
We next turned to address the oxidative state of IDHm gliomas.
Based on the NADPH-dependent production of D2HG, it was
proposed that these tumors display reduced NADPH levels (Bleeker
et al, 2010), although direct NADPH quantification has not been
provided. As a consequence, one would expect reduced glutathione
(GSH) levels, the most abundant intracellular antioxidant protecting
cells against free radicals (Townsend et al, 2003), because
glutathione reductase reduces the disulfide bond of the oxidized
form of GSH (glutathione disulfide: GSSG) in a NADPH-dependent
reaction. We measured indeed a reduced NADPH/NADP+ ratio in
IDHm xenografts compared to IDHwt, an effect which was specific
to NADPH, since the NADH/NAD+ ratio was comparable between
tumor types (Fig 5A). Interestingly, while MSI showed that the GSH
level was much higher in tumors compared to normal brain, no
significant difference was observed between IDHm and IDHwt
tumors (Fig 5B). This was confirmed by LC-MS, which also allowed
to measure GSSG. The GSSG/GSH ratios were similar in IDHm
versus IDHwt PDXs, indicating that despite reduced NADPH, IDHm
tumors appear to exhibit an adequate oxidative stress response
(Fig 5C). Comparable GSH levels between mutant and wild-type
gliomas were also found in the clinical specimen (Fig EV4).
These data suggested that GSH production may preferentially
rely on de novo biosynthesis from cysteine. The transsulfuration
pathway which supplies cysteine from methionine and cystathion-
ine (Fig 5D) was recently shown to be a significant contributor to
GSH synthesis in astrocytes (McBean, 2012). Although we were
not able to directly measure cysteine (neither by MSI nor by LC-
MS), we found lower levels of the cysteine precursor metabolite
cystathionine in IDHm gliomas by MSI (Fig 5B), suggesting high
turnover. Reduced cystathionine was confirmed by LC-MS
(Fig 5C). We next interrogated the TCGA database for the expres-
sion of the key genes involved in GSH/cysteine metabolism:
cystathionine-beta-synthase (CBS), the first enzyme of the
transsulfuration pathway, c-glutamylcysteine ligase catalytic
subunit (GCLc) which catalyzes the ligation of cysteine and gluta-
mate (Sikalidis et al, 2014), and the cystine-glutamate antiporter
(xCT, SLC7A11), responsible for cysteine uptake (Fig 5D). The
analysis was focused on IDHm versus IDHwt gliomas and further
separated IDHm gliomas based on the co-deletion of chromosome
1p/19q to distinguish the oligodendroglial and astrocytic lineage.
Based on the expression of almost 600 patients, we found that
the levels of CBS and GCLc were significantly upregulated in
IDHm compared to IDHwt gliomas (Fig 6A) supporting a higher
activation of the transsulfuration pathway. No significant dif-
ference was observed for xCT expression (SLC7A11) (Fig 6A).
Among IDHm gliomas, CBS expression was higher in IDHm-
1p/19q co-deleted gliomas compared to IDHm without 1p/19q
co-deletion, contrary to GCLc (Fig 6A). Of note, none of these
genes is present on the 1p/19q chromosome. Interestingly, when
investigating the relationship between CBS and patient prognostic,
a high CBS expression was associated with a better patient
survival in IDHm-1p/19q co-deleted gliomas, suggesting that CBS
can be used as a novel prognostic biomarker in this specific
subgroup of gliomas (Fig 6B). Taken together, our data indicate
that IDH mutation imposes a shortage of the reducing equivalents
required to maintain a balanced redox state and may rely on
cysteine availability for incorporation in GSH to ensure antioxi-
dant functions. In this context, high CBS expression may repre-
sent a marker of oxidative stress and increased reliance on the
transsulfuration pathway for cysteine generation. We suggest that
this metabolic vulnerability may offer a therapeutic window for
the treatment of IDHm glioma that awaits to be further exploited.
Discussion
Despite considerable insight in the epigenetic alterations resulting
from the gain-of-function mutation in IDH1 or IDH2, the metabolic
consequences of the mutant enzyme, whether D2HD-dependent or
not, are still poorly understood, in part due to the difficulties in
establishing IDH-mutant gliomas in culture and/or in vivo as xeno-
grafts. Here, we applied in situ metabolic profiling and LC-MS on
brain sections of glioma PDX and human glioma samples with and
without the IDH1 mutation for large-scale unbiased metabolic profil-
ing of these tumors. It should be noted that based on our current
understanding, IDH-mutant and IDH wild-type gliomas represent
biologically different entities and it is currently not clear which dif-
ferences can be directly attributed to the IDH status. Key phenotypic
differences, for example, proliferation rate and angiogenesis, are
largely inherent to the tumor subtype and may also affect the meta-
bolic signature. Notwithstanding this limitation, the IDH status is the
primary determinant of glioma subtype classification (Louis et al,
2016) and interrogating the differences between IDHwt versus IDHm
gliomas is essential to understand glioma biology. A key finding of
our study is the major differences observed in phospholipid composi-
tion in IDHm gliomas, which is in line with recent observations
made by MR spectroscopy (MRS) (Esmaeili et al, 2014; Jalbert et al,
2017). While MRS detects a signal from a pool of lipid molecules that
resonate at the same frequency, while MSI can detect the distribution
of specific metabolites that differ by their mass, which may explain
differences obtained between the two approaches. Although the
precise identification of the observed metabolites remains to be
determined, it is interesting to speculate that such metabolites might
be developed as markers of specific glioma subtypes using non-
invasive imaging approaches. The exact mechanism through which
mutant IDH affects lipid synthesis requires further insight, avenues
lie in limited citrate availability for TCA cycle and fatty acid
synthesis, and the inability of mutant IDH1 to engage in reductive
carboxylation for citrate production (Grassian et al, 2014).
It is well known that IDHm gliomas are less aggressive than their
wild-type counterparts. Here, we find a reduced energetic balance in
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IDHm gliomas, which correlates with reduced turnover of glucose
metabolism as shown by in vivo tracing of 13C6-labeled glucose.
Interestingly, recent data showed a direct inhibitory effect of D2HG
on pyruvate dehydrogenase (PDH) (Izquierdo-Garcia et al, 2015)
and ATP synthase activity (Fu et al, 2015). Reduced glycolysis is
also in line with the reported silencing of lactate dehydrogenase A
through promoter hypermethylation in IDH1m tumors (Chesnelong
et al, 2014). Thus, the reduced energy potential may be the
combined result of limited IDHwt function and of overproduction of
D2HG by the mutant enzyme directly affecting metabolic enzyme
activity and gene expression.
In vivo tracing showed minimal glucose-derived label in aKG and
D2HG suggesting that glucose is not the prevalent carbon source for
these metabolites in IDHm gliomas (Fig 3). This is in sharp contrast
with the results obtained in IDHwt glioma and normal brain, where
under the same experimental conditions both aKG and D2HG are, at
least in part, derived from glucose. Although this might be explained
by a high turnover of mitochondrial aKG, it raises the question of
alternative substrates and/or compartmentalization effects. Acetate
was recently shown to act as a bioenergetic substrate for glioblas-
toma (Mashimo et al, 2014), and NAA and NAAG supplemented to
glioblastoma cells were found to support tumor growth (Long et al,
2013). NAA and NAAG are involved in the acetate metabolism
which also regulates lipid synthesis and histone acetylation (Gao
et al, 2016). In line with earlier data (Reitman et al, 2011), NAAG
levels were heterogeneous in IDHm gliomas, suggesting differential
activation of metabolic pathways. In vivo experiments with stable
acetate tracers will be required to evaluate the contribution of dif-
ferent acetate sources as a bioenergetic fuel and source of D2HG in
IDHm glioma.
In agreement with our previous work (Tardito et al, 2015),
isotopically labeled glutamine intravenously injected in glioma
xenografts was neither efficiently taken up by the brain nor by
tumors independent of their IDH status (Fig EV3A); thus, it can be
ruled out that blood-borne glutamine is a relevant source of carbons
for D2HG production in IDHm glioma. This is in line with an earlier
study indicating that blood-borne glutamine is not significantly
metabolized in glioma xenografts (Marin-Valencia et al, 2012).
Several in vitro studies suggested increased reliance of IDHm cells
on glutamine-dependent anaplerosis (Reitman et al, 2011; Ohka
et al, 2014). Transcriptional silencing or chemical inhibition of
glutaminase, the enzyme converting glutamine to glutamate, led to
reduced cell proliferation in IDHm cells in vitro (Seltzer et al, 2010;
Emadi et al, 2014). However, this is not supported by our in vivo
data since in both IDHwt and IDHm tumors, the cataplerotic activity
of glutamine synthetase (GS), as opposed to the anaplerotic activity
of glutaminase, was detectable (13C2 glutamine in Fig 3C). More-
over, in the clinical samples, the total level of glutamate was signifi-
cantly reduced in IDHm gliomas, while glutamine was comparable
in both tumor types and close to normal brain values. In the brain
context, where glutamate can be provided by astrocytes, the impor-
tance of tumor-autonomous glutaminolysis appears to be minimal
(Tardito et al, 2015) and the high glutamate concentrations in the
brain may render gliomas less vulnerable to glucose-derived meta-
bolic fluctuations (van Lith et al, 2014). Taken together these
aspects highlight the importance of studying brain tumor metabo-
lism in vivo within its organ-specific microenvironment that affects
the metabolic behavior of glioma cells.
Earlier work on wild-type IDH demonstrated its crucial role in
the maintenance of the cellular redox state, presumably through its
NADPH-producing activity (Jo et al, 2001; Lee et al, 2002). In line
with previous studies (Bleeker et al, 2010; Molenaar et al, 2015),
we found a small reduction in NADPH activity in IDHm glioma
in vivo, yet surprisingly GSH levels were maintained, which is in
contrast to cell lines engineered to overexpress the mutant enzyme
(Mohrenz et al, 2013; Shi et al, 2014, 2015). De novo GSH synthesis
relies on cysteine availability, which can be replenished via extracel-
lular import by the cystine-glutamate antiporter xCT or via intracel-
lular synthesis through the transsulfuration pathway (McBean,
2012). Both routes are important for maintaining the antioxidant
potential in cells under oxidative stress when the demand for GSH is
elevated (Ogunrinu & Sontheimer, 2010; McBean, 2012). The
increased expression of CBS and GCLc in IDHm gliomas supports
the idea that IDHm tumors may preferentially utilize the transsulfu-
ration pathway for GSH synthesis. The importance of CBS and GCL
in tumorigenesis has recently been highlighted (Takano et al, 2014;
Harris et al, 2015). Here, we identify CBS not only as a novel prog-
nostic marker for 1p/19q co-deleted IDHm gliomas (ODG subtype),
but also as a potential target to tilt the balance toward high-oxida-
tive stress in IDHm gliomas. In conclusion, the present study
provides important insight into the metabolism of IDHm and IDHwt
gliomas and points to hitherto unrecognized metabolic vulnerabili-
ties imposed by the activity of mutant IDH.
Materials and Methods
Patient samples
Glioma samples for PDX generation were collected at the Centre
Hospitalier in Luxembourg (Neurosurgical Department, CHL) or the
Haukeland University Hospital (Bergen, Norway) from patients who
have given informed consent. Clinical samples for LC-MS analysis
were obtained from 13 patients from the Haukeland Hospital,
Bergen, Norway, where tissue fragments were stereotactically
sampled (~25 mg) during the operation and snap-frozen. Diagnosis
and IDH status of clinical samples were determined by classical
neuropathology and immunohistochemistry for IDH1 (6 IDHm
gliomas, 7 IDHwt gliomas). IDH1 status, 1p/19q co-deletion, hyper-
methylation status, and grade are indicated in Table EV6. D2HG
production was verified by LC-MS confirming the IDHm status of
the samples (Fig EV4). All studies were conducted according to the
Declaration of Helsinki and with approval from the local ethics
committees (National Ethics Committee for Research (CNER)
Luxembourg (ADAPT protocol REC-LRNO-20110708) and local
ethics committee Haukeland University Hospital, Bergen (REK
2010/130-2)).
Patient-derived glioma xenografts
Patient-derived glioma xenografts (PDX) were generated in NOD/
Scid mice (male or female, at least 2 months of age) as previously
described (Golebiewska et al, 2013; Navis et al, 2013; Sanzey et al,
2015; Bougnaud et al, 2016) from 3 IDHwt gliomas (P3, P8, and
T434) and 3 IDHm gliomas (E478, T186, and T394). Histopathologi-
cal and molecular diagnostics are shown in Table 1. Orthotopic
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xenografts were maintained by serial transplantation in the brain of
mice, using either organotypic spheroids established in short-term
culture (minced tissue fragments maintained for 7–10 days in flasks
coated with 0.75% agar under standard tissue culture conditions)
(Bougnaud et al, 2016) for IDHwt tumors, or by direct inoculation
of fresh tumor material into the right frontal cortex (IDHm tumors).
All mice were housed in an isolated specific-pathogen-free environ-
ment. Food and water were supplied ad libitum. Mice were sacri-
ficed at the first signs of neurological symptoms (locomotor
problems, uncontrolled movements) or behavioral abnormalities
(prostration, hyperactivity); the brains were dissected out and cut
into two pieces along the coronal plane at the tumor core. The half
brains were immediately snap-frozen in isopentane/liquid nitrogen
for preparation of either cryosections for MSI or for metabolite
extraction for LC-MS. The handling of the animals and the surgical
procedures were performed in accordance with the European Direc-
tive on animal experimentation (2010/63/EU) and were approved
by the institutional and national authorities responsible for animal
experiments in Luxembourg (Protocol LRNO-2014-03).
Mass spectrometry imaging (MSI)
Ten-micrometer-thick cryosections of glioma xenografts were
prepared on a cryostat (Microme HM560), set at 21C for
specimen and blade parameters, and mounted on conductive slides
(Indium Tin Oxide, ITO) for MSI and cryodesiccated for 30 min.
Slides were then transferred into a desiccator under vacuum for 30
min to complete drying and scanned for next step (teaching with
imaging software). Matrix deposit for MSI : 9-AA (9-Amino Acri-
dine) matrix was prepared at 5 mg/ml in 100% MeOH (LC-MS
grade) and sprayed onto the slide with the Suncollect sprayer
(Sunchrom, GmbH Germany). Analyses were performed on a Matrix
Assisted Laser Desorption Ionisation–Fourier Transform Ion Cyclo-
tron Resonance instrument (MALDI-FTICR) 7.0 T (Bruker Daltonics
GmbH, Bremen, Germany) in full scan negative mode within 70–
1,000 Da mass range at 100-lm spatial resolution. The horizontal
axis in a mass spectrum is expressed in units of m/z, which repre-
sents the mass over charge (number of ions) ratio. For the untar-
geted analysis, 50 pixels of analysis from the imaging data (i.e., 50
mass spectra) per region of interest (ROI) were selected to run a
statistical test on ClinProTools 3.0 software (Bruker, Germany)
(Table EV1) using a threshold of signal to noise of 5 to compare the
peaks between conditions. Recalibration, average peak list calcula-
tion, and peak calculation from ClinProTools allowed obtaining
statistical results with metabolites using t-test. Relevant metabolites
were considered for P value < 0.01 (from t-test) and fold change > 3
between conditions (Tables EV2 and EV3). MSI data were operator-
verified to check the imaging data and suppress false positives.
Imabiotech metabolite database as well as Metlin and the Human
Metabolome DataBase (HMDB) were interrogated for identification
of the compounds found with ClinProTools. Mass accuracy was set
at 10 ppm, and lists of metabolites were established with their struc-
tures. When several hits matched with the m/z of interest, one
representative compound was selected for presentation in Tables
EV2 and EV3. For the targeted approach, measurement regions
included identical large ROIs selected in biological sections and
were analyzed by Fleximaging 4.0 software (Bruker Daltonics
GmbH, Germany). Initially for each condition (PDX or control brain
without implantation), three sections from three animals were
analyzed for quantification. In a second step, sections were
analyzed from six different PDX models. To ensure the correct
assignment of specific metabolites, we performed fragmentation
analysis to confirm their identity and were able to validate nine of
16 compounds including glutamate (Glu), glutamine (Gln), N-acetyl
aspartate (NAA), N-acetyl aspartyl glutamate (NAAG), cystathion-
ine, reduced glutathione (GSH), ascorbic acid, citric acid, and cyti-
dine (Table EV4). Metabolites were validated if at least one
fragment was found to be relevant.
LESA-nESI-FTICR was applied for specific metabolites that were
undetectable by MALDI as described previously (Navis et al, 2013).
A Nanomate Triversa (Advion) in “Liquid Extraction Surface Analy-
sis” (LESA) mode coupled to a nano-ElectroSpray Ionisation (nano-
ESI) source on the FTICR was used to extract analytes from biologi-
cal sections with an extraction solution. Sample plates were cooled
down to 12°C during analyses to limit degradation or secondary
reactions. Fragmentation was performed in positive and negative
mode within the collision cell of the SolariX after isolation of the
parent compound in the quadrupole to confirm the identity of the
metabolites. Spray parameters were set as follows: voltage to apply
1.30 kV and gas pressure 0.40 psi. Extraction solvent consisted of
65:15:20 MeOH:IPA: water + 5 mM ammonium acetate using LC-
MS quality solvents. Isolation of the ion in the quadrupole within a
2–5 mDa window and fragmentation with appropriate collision
energies in the collision cell (qCID) (15 V). After MALDI analysis,
the 9-AA matrix was removed from the slide with MeOH and hema-
toxylin–eosin (H&E) staining was performed to visualize the tumor
area. This image was later implemented into QuantinetixTM software
for data analysis by overlaying the optical image with molecular
images. An intensity-dependent color code shows the relative
amount of a specific compound (m/z value) throughout the tissue
section, which was also used for quantification (log intensity
values).
Isotopically labeled reference compounds and tissue extinction
coefficient for MSI
The signal obtained by MALDI on tissue sections can be modulated
by the chemical composition of the tissue and thus can differ from
one tissue to another. This can be controlled for by determining the
tissue extinction coefficient (TEC) for each metabolite. Since the
metabolites are endogenous molecules in the brain, labeled forms
had to be used in this approach. Therefore, for the TEC determina-
tion, isotopically labeled compounds were mixed with the 9-AA
matrix (5 mg/ml in MeOH) to achieve 20 lM final concentration,
and the final mixture was sprayed on the entire slide for analysis.
For TEC analysis, an additional region was selected outside tissue
sections as a control area (no tissue effect in this area) for calcula-
tions of TEC values, defined as the ratio of compound signal in the
tissue section to the compound signal outside the tissue section. The
following compounds were analyzed: NAA-d3, NAAG-d3 (Spaglu-
mic acid-d3), L-cystathionine-d4, GSH 13C, 15N and GSSG 13C,15N.
NAA-d3 was purchased from CDN isotopes, all other itotopically
labeled compounds from Toronto Research Chemical, Canada. LC-
MS grade solvents were used for sample preparation. Overall, the
TEC values were comparable for the different regions (mutant or
wild-type tumor, contralateral brain, and control brain), indicating
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that for the majority of compounds, the quantification is not likely
to be affected by strong tissue effects (Table EV5). Except for GSSG,
which was excluded from the present data, since all isotopic
compounds were simultaneously present in the mix, oxidation reac-
tions cannot be excluded, which may explain differences in GSSG
values. Data were treated with Fleximaging 4.0 (Bruker, Germany),
proprietary softwares QuantinetixTM 1.7, and MultimagingTM 1.0.30
(ImaBiotech, Loos, France).
LC-MS analysis
LC-MS analysis was run on snap-frozen tissue of six PDX samples
and 13 clinical samples. Each sample was analyzed in three
replicates. For metabolite extraction, a 5-mm metal bead (Qiagen,
No69989) and extraction buffer (methanol/acetonitrile/water-50/
30/20) containing 100 ng/ml HEPES for internal standard purpose
(Sigma, H4034) were added to the tissue at a volume/weight ratio
of 25 ll/mg. The tissue was disrupted in a bead mill (Qiagen,
Tissuelyzer, Hombrechtikan, Switzerland) with 2 cycles (2 × 20 s/
20 MHz) before vortexing on an Eppendorf Thermomixer at 2°C/
20 min/1,400 rpm. The extract was clarified by centrifugation
(15 min/13,362 g/4°C in an Eppendorf centrifuge) and transferred
in fresh tubes and stored at 80°C. LC-MS analysis was performed
as previously described (Tardito et al, 2015). Tumor extracts were
compared to extracts from contralateral mouse brain for reliable
comparison between the two models.
Statistical analysis of MS data
For statistical analysis of mass spectrometry (MS) data, we used
the standard tests implemented in the “stats” package of R. In
order to be able to apply parametric statistical tests, the MS inten-
sity data were log-transformed. To test the applicability of the
normality assumption, we first normalized log intensities between
metabolites (by mean centering and scaling) and then submitted
the united data vector to Shapiro and Kolmogorov–Smirnov tests.
Both parametrical tests (ANOVA and unpaired t-test) and non-
parametrical Wilcoxon (Mann–Whitney) test were used to compare
mean values of log intensities for MSI and LC-MS data depending
on data quantity and number of compared groups. Tukey’s honest
significant differences were used for post hoc analysis of ANOVA
results for LC-MS data (not shown). In order to compare the large
sets of MSI data between several samples, we applied Wilcoxon
test with the most stringent Bonferroni adjustment. As, despite this
stringency, the large number of data points in MSI data may lead
to overestimation of the significance, mean MSI intensities were
considered as well. For all MS data shown, P-values are based on
unpaired two-tailed t-test of mean abundances of metabolites
between PDX with and without IDH1 mutation. Whenever error
bars are shown in the figures with metabolite abundances, they
correspond to standard errors of the mean, except for box plots that
follow the classical visualization rules and are based on quartiles.
Testing normality of the MSI data gave the P-value of 0.46
and 0.98 for Shapiro and Kolmogorov–Smirnov tests concor-
dantly, suggesting that the log-transformed data may come from
the normal distribution. For global LC-MS data, we observed low
P-value for Shapiro test (P-value = 2.5e-7) and non-significant
Kolmogorov–Smirnov test (P-value = 0.24). However, violations of
normality were caused by a single sample (P3_NC1331): If it is
excluded, both tests do not show significant deviation from
normality (Shapiro’s P-value = 0.062, Kolmogorov–Smirnov’s
P-value = 0.083).
Administration of 13C-labeled tracers
U-13C6-Glucose (
13C6-Glc) or U-
13C5 glutamine (
13C5-Gln) tracer from
Cambridge Isotope Laboratories (CIL, USA, Andover, MA) was
dissolved in saline solution (0.9% NaCl) and administered by a
single bolus injection in the tail vein to ensure doses of 1 mg/g for
the 13C6-Glc or 0.15 mg/g for
13C5-Gln. The animals were sacrificed
22 min after tracer administration, and brains were cryopreserved
in isopentane for LC-MS analysis. For each PDX, three xenografted
mice were analyzed per tracer.
NADP/NADPH quantification
Relative quantification of the oxidized and reduced adenine dinu-
cleotide phosphates (NADP+ and NADPH) in tissue extracts was
obtained with the bioluminescent NADP/NADPH-GloTM Assay
(Promega, G9081). For comparative analysis, we used a standard-
ized extraction procedure with a bead mill (TissueLyser II, Qiagen,
20 Hz/20 s) for tissue disruption and metabolite extraction and a
buffer/tissue ratio of 50 ll of the recommended extraction buffer
per milligram of tissue. Luminescence signals were measured in a
96-well format in a Lumistar plate reader. Total oxidized and
reduced nicotinamide amounts expressed in relative luminescence
units served to determine NADP/NADPH ratios in tissue extracts.
Calibration of the assay was done with a NADP+ standard curve.
TCGA analysis
Glioma patient data of the TCGA cohort (fused LGG and GBM
(Ceccarelli et al, 2016)) were obtained from cBioPortal (Gao et al,
The paper explained
Problem
Gliomas are malignant brain tumors which are currently incurable.
Point mutations in the enzyme isocitrate dehydrogenase (IDH) are
thought to be a driver for a major subset of gliomas, leading to the
generation of the oncometabolite D2HG and subsequent abnormalities
in gene expression. The metabolic consequences of the mutation are
less well understood.
Results
The key results of the present work include the following: (i) novel
insight into aberrant lipid metabolism in IDH-mutant gliomas, (ii)
demonstration of low energy potential in IDH-mutant gliomas, (iii)
identification of potential compensatory pathways to maintain redox
balance and establishing a novel prognostic factor in patients with
oligodendroglial glioma subtype.
Impact
The present study uncovers a mutant IDH-specific metabolic land-
scape which is clinically relevant and highlights novel metabolic
vulnerabilities in IDH-mutant gliomas that may be therapeutically
exploited.
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2013) and analyzed using R software. Analysis of TCGA database
cohort was performed as follows: Expression data were based on
RNA-Seq for IDHwt (n = 220), for IDHm with 1p/19q co-deletion
(n = 151), and IDHm without co-deletion (n = 226), total n = 597.
Center lines of the box plots show the medians; box limits indicate
the 25th and 75th percentiles; outliers are represented by dots.
Notches indicate 1.58 × IQR/sqrt(n) and give 95% confidence that
two medians differ (Chambers et al, 1983). For Kaplan–Meier
survival analyses, gene expression median was calculated indepen-
dently for each clinical group. Comparison of survival curves
was done using log-rank (Mantel–Cox) test, using GraphPad Prism
software.
Expanded View for this article is available online.
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